Share-based Payment Arrangement, Expense of Lexeo Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lexeo Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Lexeo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,651,000, a 30% decline year-over-year.
  • Lexeo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,926,000, a 32% increase year-over-year.
  • Lexeo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,474,000, a 310% increase from 2023.
  • Lexeo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,043,000, a 71% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Lexeo Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,926,000 $2,651,000 -$1,139,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $14,065,000 $3,071,000 +$225,000 +7.9% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $13,840,000 $3,697,000 +$1,366,000 +59% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $12,474,000 $3,507,000 +$2,704,000 +337% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $9,770,000 $3,790,000 +$2,916,000 +334% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $6,854,000 $2,846,000 +$1,877,000 +194% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $4,977,000 $2,331,000 +$1,934,000 +487% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $3,043,000 $803,000 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $874,000 +$443,000 +103% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $969,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $397,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $431,000 01 Jul 2022 30 Sep 2022 10-Q 11 Dec 2023 2023 Q3

Lexeo Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,474,000 +$9,431,000 +310% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $3,043,000 +$1,262,000 +71% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $1,781,000 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.